Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageCelldex Therapeutics, Inc., which we refer to as “Celldex,” “we,” “us,” “our” or the “Company,” is a biopharmaceutical company dedicated to exploring the science of mast cell biology and developing therapeutic antibodies which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Business segments
Q2 2025 · $730.0KThe company’s own SEC segment disclosure.
- Grant$723.0K99%
- Service$7.0K1%
Celldex Therapeutics, Inc. (CLDX) reported revenue of $22K in Q2 2026 (quarter ended June 30, 2026), down 97% from the same quarter a year earlier. That came with net loss of $74M. For the full year FY2025, revenue was $1.5M (−78% year on year) and net income −$259M. Its largest product in 2025-Q2 was Grant at $723K, 99% of the disclosed total, just ahead of Service at 1.0%.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.